Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

BIOGEN INC.

(BIIB)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op BIOGEN INC.
03/12Drugmakers cut prices by 62% on average to get China state insurance listing
01/12Sage Therapeutics, Biogen Report Positive Data From Antidepressant Drug Candidate Zuran..
01/12Viatris Wins Court Tussle Against Biogen as US Appeals Court Upholds Earlier Patent Rul..
01/12Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the O..
01/12Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the O..
30/11Biogen Loses Appeals Court Bid to Revive Multiple Sclerosis Drug Patent
30/11US Court of Appeals Affirms District Court Decision That Biogen's 2028 Tecfidera Patent..
22/11Biogen's Alzheimer's Drug Reportedly Caused Brain Swelling in Over One-Third of Patient..
22/11Study Shows Biogen's Alzheimer's Drug Reportedly Shows Brain Swelling in 35% of Patient..
22/11BIOGEN : Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormaliti..
21/11Presseschau vom Wochenende 45 (20./21. November)
19/11BIOGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
18/11Biogen Inc. - Update on Regulatory Review of Aducanumab in the European Union
18/11Asian Stock Markets Wobble on Tech, Property Outlooks
18/11Nikkei 225 Off 0.3% Despite News on Government Stimulus Package
18/11Novartis Said Considering Takeover in Biotech Sector
18/11Tokyo termine dans le rouge derrière Wall Street
18/11Nikkei dips but pares losses after report on larger stimulus
18/11European Medicines Agency Committee Gives Negative Trend Vote on Biogen's Alzheimer's D..
18/11Japanese shares dip as inflation worries hit global stocks
18/11Tokyo reflue au diapason de Wall Street
17/11GLOBAL MARKETS LIVE : Tesla, Experian, Roche, Activision, Amazon...
17/11The return of inflation fears
17/11BIOGEN : vers un avis négatif du CHMP dans Alzheimer
17/11Health Care Stocks Flat To Lower Premarket Wednesday
17/11Biogen Inc. - The European Commission Grants Marketing Authorization for VUMERITY (diro..
17/11Les valeurs à suivre aujourd'hui à Wall Street Mercredi 17 novembre 2021
17/11BIOGEN : mauvaise nouvelle en Europe pour son traitement contre la maladie d'Alzheimer
17/11Biogen, Eisai's Alzheimer's Drug Candidate Receives Negative Trend Vote by European Reg..
17/11Biogen's Alzheimer's Drug Gets Negative Trend Vote in EU
17/11Update on Regulatory Review of Aducanumab in the European Union
17/11Biogen Inc. and Eisai Co., Ltd. Announces an Update on the Ongoing Review of the Market..
17/11BIOGEN : Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development - F..
17/11BIOGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
16/11Biogen Secures European Marketing Approval for Multiple Sclerosis Treatment
16/11Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
16/11The European Commission Grants Marketing Authorization for VUMERITYģ (diroximel fumarat..
16/11The European Commission Grants Marketing Authorization for VUMERITY? (diroximel fumarat..
16/11Biogen's research chief Alfred Sandrock to retire
16/11Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
16/11Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
16/11Biogen Inc. Announces Executive Changes
15/11Eisai presents new analysis of lecanemab clinical efficacy results from phase 2b study ..
15/11Eisai Co., Ltd. - INTRODUCTION OF FIRST-OF-A-KIND PLASMA-BASED BIOMARKER SCREENING TO F..
15/11Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index fo..
12/11REFILE-UPDATE 4-Biden will nominate industry-friendly Califf to lead U.S. FDA
12/11Wall Street rises on J&J, Big Tech boost
12/11TODAY ON WALL STREET : Out with the old
12/11Biogen Inc. - Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening to Facil..
12/11Biogen Inc. - New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effe..
12/11Health Care Stocks Gain Premarket Friday
12/11Biogen, Eisai Alzheimer Treatment Shows Positive Signs in Advanced Trial
11/11Biogen Says Clinical Trial Data Show Aduhelm Reduced Levels of Protein Linked With Alzh..
11/11New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on B..
11/11Biogen Inc. and Eisai Co., Ltd. Announce New Phase 3 Data Show Positive Correlation Bet..
11/11Biogen says Aduhelm lowers levels of second protein associated with Alzheimer's
11/11Biogen, Eisai Disclose Lecanemab Clinical Efficacy Results in Patients With Alzheimer's..
11/11Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identifi..
11/11Eisai Co., Ltd. and Biogen Inc. Announces Presentation About Exploring Use of Plasma-Ba..
11/11Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study ..
11/11Eisai Co., Ltd. and Biogen Inc. Present New Analysis of Lecanemab Clinical Efficacy Res..
11/11Darmstädter Merck verdient weniger - Corona-Boom treibt weiter an
10/11Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data Fr..
10/11Eisai Co., Ltd. and Biogen Inc. Presents Late-Breaker Updates on Lecanemab Clinical, Bi..
10/11Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data fr..
10/11Roche To Price Alzheimer's Drug Below Rival Biogen's Aduhelm, Executive Says
10/11Roche will Alzheimer-Medikament konkurrenzfähig anbieten
10/11WDH : Roche will Alzheimer-Medikament konkurrenzfähig anbieten
10/11Roche executive says Alzheimer's drug price will be competitive
09/11Health Care Edges Lower On Defensive Bias - Health Care Roundup
09/11Biogen probes death of Aduhelm user after brain swelling
04/11Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinic..
03/11Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinic..
03/11Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinic..
02/11A LETTER FROM ALPHONSE GALDES, PH.D. : It's Time for Companies to Act Like the Climate Cri..
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op BIOGEN INC.
27/01/22